Femasys Signs Distribution Agreement with McKesson Medical-Surgical for FemCerv Device for Diagnosis of Cervical Cancer

   Femasys Signs Distribution Agreement with McKesson Medical-Surgical for
               FemCerv Device for Diagnosis of Cervical Cancer

PR Newswire

ATLANTA, July 8, 2014

ATLANTA, July 8, 2014 /PRNewswire/ --Femasys Inc., an emerging medical device
developer of women's healthcare solutions, announced today that it has entered
into a nationwide distribution agreement with McKesson Medical-Surgical to
sell and distribute Femasys' FEMCERV® Endocervical Sampler. FEMCERV collects
a tissue sample of a woman's endocervical canal for histological analysis when
cervical cancer is suspected.

Under terms of the agreement, McKesson Medical-Surgical will sell and
distribute the FEMCERV device nationwide through its sales force. Kathy
Lee-Sepsick, President & CEO of Femasys commented, "We are thrilled to create
an alliance with McKesson Medical-Surgical in bringing FEMCERV to the market
as a novel new advancement in tissue sample collection for cervical cancer
diagnosis. With McKesson Medical-Surgical's extensive market presence,
physicians will gain access across the country to this much needed technology
that has been designed with the woman and her anatomy in mind. Clinical data
has demonstrated that physicians find FEMCERV easy to insert and well
tolerated by almost all patients, who experienced mild or no discomfort."

"We're pleased to offer Femasys' FEMCERV product to our customers," said Joan
Eliasek, Senior Vice President, Supplier Management, McKesson
Medical-Surgical. "As a company, we are in business for one reason: better
health. And fighting cancer is a major aspect of better health in our country.
We are glad to offer products to our customers that help them deliver better
care for their patients."

About FEMCERV
FEMCERV is intended for women who have received an abnormal pap smear result
or have other factors that require a sampling of her cervical canal (i.e.
cervical lesions extending into the canal or when there is undiagnosed uterine
bleeding). The device minimizes the risk of incomplete sampling and optimizes
diagnostic acuity by collecting a complete 360 degreesample, while protecting
the sample from contamination. Endocervical curettage has the potential to
decrease the number of unnecessary surgical treatments and to play a role in
reducing the number of undiagnosed cases of cervical cancer. For additional
information on the FEMCERV device, please visit www.femcerv.com.

About McKesson
McKesson Medical-Surgical's parent, McKesson Corporation, currently ranked
14th on the FORTUNE 500 list, is a healthcare services and information
technology company dedicated to making the business of healthcare run better.
McKesson Medical-Surgical works with payers, hospitals, physician offices,
pharmacies, pharmaceutical companies and others across the spectrum of care to
build healthier organizations that deliver better care to patients in every
setting. McKesson Medical-Surgical helps its customers improve their
financial, operational, and clinical performance with solutions that include
pharmaceutical and medical-surgical supply management, healthcare information
technology, and business and clinical services. For more information, please
visit http://www.mckesson.com.

About Femasys Inc.
Femasys Inc., based in Atlanta, GA, is a privately held corporation committed
to advancing women's healthcare worldwide by expanding options for women with
innovative medical devices and next generation advancements providing
significant clinical impact.

For additional information on Femasys and our other products, please visit
www.femasys.com.

Business Development Contact:
Steven Damon, 770.598.6446, sdamon@femasys.com

Media Contact:
Jerry Fink, 770.500.3910, jfink@femasys.com

SOURCE Femasys Inc.

Website: http://www.femasys.com
 
Press spacebar to pause and continue. Press esc to stop.